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Abstract 
Introduction: Neuroendocrine neoplasms (NENs) are a rare and heterogeneous group of tumours, with a variety of primary origins and 
variable aggressiveness. NENs with an atypical primary origin, such as breast and retroperitoneal NENs, are extremely rare. As a conse-
quence, an established diagnostic and therapeutic strategy in this particular subgroup is lacking. The combination of capecitabine and te-
mozolomide, called CAPTEM regimen, has produced promising response rates in patients with grade 1 or 2 neuroendocrine tumours of 
multiple origins.
Case presentation: The first is a case of a 68-year-old woman with a metastatic primary breast neuroendocrine tumour, treated with cispla-
tin plus etoposide as first line, followed by CAV scheme (cyclophosphamide, doxorubicin, and vincristine), and subsequently treated, in 
third line with the CAPTEM regimen, obtaining radiological response and good tolerance. The second is the case of a 66-year-old woman 
affected by a metastatic primitive retroperitoneal NET G2. The patient progressed after a somatostatin analogue-based first line, whereas 
the CAPTEM regimen led to a partial and durable response with a favourable safety profile. 
Conclusions: CAPTEM chemotherapy has been shown to be an active and safe therapeutic option in advanced, metastatic G1/2 atypical 
primary NENs. (Endokrynol Pol 2019; 70 (4): 380–383)
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Introduction 
Neuroendocrine neoplasms (NENs) are a rare and het-
erogeneous group of tumours, with a variety of primary 
origins and variable aggressiveness [1]. However, in 
clinical daily practice, therapeutic management is de-
termined by the combined evaluation of the tumoural 
morphology, the proliferation index (Ki67) value, and 
the clinical presentation (tumour burden, rapidity of 
growth, patient’s performance status), whatever the 
primary origin. Of note, clinical trials and the most 
relevant retrospective studies generally do not include 
patients with NENs of atypical origin, thus a stan-
dardised therapeutic strategy has not been established 
in this particular subgroup. As a consequence, in clinical 
practice, well- and moderately-differentiated NENs 
(defined as neuroendocrine tumours with grading 1/2 
or NENs G1/2) with atypical primary sites of origin, 
such as primary breast [2] and primary retroperitoneal 
NETs [3], are treated like more common primary ones 
– gastroenteropancreatic and thoracic NENs. However, 
increasing literature data suggest that the combina-
tion chemotherapy of capecitabine and temozolomide 
(CAPTEM) could be a potentially useful treatment op-
tion for patients with grade 1/2 NENs of multiple origins 
[4–10]. Here we describe two cases of G1/2 NENs with 
atypical primary treated with CAPTEM regimen.
Case reports
Case 1
A 68-year-old woman, suffering from neuroendocrine 
primary breast cancer, with bone, lymph node, lung, 
brain, liver, and left adrenal metastases is described 
herein. Following the auto-detection of a left breast 
node, in June 2010 the patient performed an ultrasound 
with evidence of two suspicious lesions in the left breast. 
In September 2010 the patient underwent a left breast 
lumpectomy with sentinel lymph node dissection. At 
histopathologic examination, the infiltrating tumour 
revealed features of moderately differentiated, G2, 
pT1bN1 neuroendocrine tumour, with a multifocal com-
ponent. The left axillary sentinel lymph node showed 
metastatic deposits with the same histomorphology. 
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disease, but progressive severe cognitive deterioration 
led to cessation of active anticancer treatment. After six 
months the patient died.
Case 2
In 2011, a 66-year-old woman performed an abdominal 
CT scan for persistent abdominal pain, with evidence 
of retroperitoneal neoplastic lesion. The woman had 
a remote pathological history of autoimmune hypo-
thyroidism that was well controlled by replacement 
therapy, parathyroid adenoma excision, and type 2 
diabetes requiring oral hypoglycaemic treatment. The 
patient underwent a radical surgical removal of the 
disease. Histopathologic examination showed a mod-
erately differentiated neuroendocrine tumour (NET); 
Ki-67 value amounted to 4% (NET G2); necrosis and 
angioinvasion were absent. The screening for inherited 
endocrine syndromes was negative. Post-surgery Gal-
lium 68 PET-CT scan was negative. No adjuvant therapy 
was performed, and clinical-radiological follow-up 
was set. Three years after diagnosis, a CT scan showed 
liver disease progression, confirmed by biopsy. At the 
clinical evaluation, the patient presented carcinoid 
syndrome, reporting frequent episodes of flushing and 
diarrhoea. A first-line therapy with the intramuscular 
somatostatin analogue Octreotide LAR 30 mg every 28 
days was started, with a significant improvement of the 
carcinoid syndrome symptoms. A worsening of diabetes 
was observed, with the need for insulin therapy. After 
about one year of therapy, in November 2015, a total 
body CT scan showed further hepatic disease progres-
sion. The case was discussed within the neuroendocrine 
multidisciplinary board of our centre, and a second-line 
CAPTEM chemotherapy was proposed. After the 
first cycle of chemotherapy, the patient experienced 
grade 3 thrombocytopaenia, and a dose reduction 
was performed for a further eight cycles. In July 2016, 
after hepatic oligo-progression of the disease, the case 
was discussed again in the neuroendocrine-dedicated 
multidisciplinary team, and a hepatic trans-arterial 
chemoembolism with epirubicin was performed, ob-
taining a partial response. In June 2018, at 20 months of 
follow-up, the patient was in good clinical conditions, 
without carcinoid syndrome or disease progression, 
receiving octreotide LAR treatment.
Discussion
A variety of therapeutic strategies, such as somatostatin 
analogues, molecular therapies, peptide receptor radio-
nuclide therapy (PRRT), and chemotherapy regimens, 
have been investigated and approved in inoperable or 
metastatic G1/G2 NET patients [11]. However, standard 
cytotoxic agents commonly used in clinical practice 
Immunohistochemistry (IHC) studies with antibodies 
directed against chromogranin, synaptophysin, oes-
trogen receptor (ER), progesterone receptor (PgR), and 
HER2/neu, were carried out. More than 90% of tumour 
cells, in both breast and lymph nodes, were positive for 
chromogranin and synaptophysin, whereas ER, PgR, 
and HER2 were negative. Ki-67 was 16%; somatostatin 
receptor results were negative. Thus, in October 2010, 
the patient underwent an axillary left dissection. At 
the histologic assessment, reactive hyperplasia was 
detected in all 11 examined lymph nodes. Both basal 
serum chromogranin A and NSE were within normal 
ranges. The patient did not show clinical signs of 
carcinoid syndrome. A postoperative total body (TB) 
computed tomography (CT) scan was performed, 
with the evidence of bilateral mediastinal pathological 
lymph nodes, liver, lung, left adrenal metastases, three 
secondary brain lesions, and bone lytic secondary le-
sions in the spine and ribs. The result of the bone scan 
and In-111 Octreoscan scintigraphy was negative. From 
November 2010 to March 2011 the patient received 
the combination of cisplatin and etoposide as first-line 
chemotherapy, considering the high tumour burden 
and the patient’s good clinical condition. The patient 
developed grade 3 haematological toxicity and fatigue; 
therefore, a dose reduction was needed. After six cycles 
of treatment, the restaging CT scan showed a partial re-
sponse of bone, lymph node, hepatic, adrenal, and lung 
lesions, whereas brain lesions were stable. Therefore, 
the patient underwent pan-encephalic palliative radio-
therapy, with a total dose of 30 Gy. From July 2011 to 
May 2013, a “wait and see” strategy was carried out, and 
bisphosphonates therapy (zoledronic acid) was added 
for 24 months.  Due to disease liver progression, from 
June to November 2013, the patient received eight cycles 
of CAV chemotherapy (cyclophosphamide, doxorubi-
cin, and vincristine) with the onset of G3 neurotoxicity. 
In November 2013, the restaging TB CT scan showed 
a partial response. A “wait and see strategy” was 
chosen again. On March 2015 after a new radiological 
progression, a fine needle biopsy was performed. The 
histopathological evaluation detected neuroendocrine 
differentiation cells with a Ki-67 of 2%; the IHC ER, PgR, 
and ERB-B2 were negative. In April 2015, a third-line 
chemotherapy with oral capecitabine (2000 mg/m2 
daily, days 1–14) and temozolomide (200 mg/m2 once 
daily, days 10–14) every 28 days (CAPTEM scheme) was 
started. After six cycles, the patient obtained a radiologi-
cal reduction of brain lesions and the stability of the 
other metastatic lesions. The patient experienced grade 
3 thrombocytopaenia after four cycles of therapy, so 
a 25% dose reduction was performed for a further two 
cycles, followed by a 50% dose reduction for a further 
two cycles. In January 2016, a TB CT scan showed stable 
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have demonstrated limited efficacy [12]. The associa-
tion of temozolomide, an orally administered alkylating 
agent that methylates the O6-residues of guanine, thus 
preventing DNA duplication during cell proliferation 
and inducing cell death, and capecitabine, the orally 
administered precursor of 5-fluorouracil (5-FU), have 
demonstrated activity in the treatment of G1/G2 NET 
of pancreatic and non-pancreatic origin with a favour-
able toxicity profile [6, 10]. Recently, the most common 
mechanism of resistance to temozolomide, consisting 
of high expression of O6-methylguanine DNA meth-
yltransferase (MGMT), a DNA repair enzyme able to 
reverse the anti-tumour effect of this alkylating drug, 
has been identified [13]. In vitro studies showed that 
5-FU depletes tumour levels of MGMT [14], and this 
represents a strong rationale to test the synergistic 
activity of capecitabine and temozolomide.
Recently a randomised phase II trial compared 
capecitabine alone and the CAPTEM regimen in meta-
static pancreatic NET. Temozolomide and capecitabine 
improved the progression-free survival (PFS) of 
8.3 months (HR 0.58) compared to temozolomide alone. 
This was the first prospective randomised trial of these 
agents and showed the longest PFS reported for pan-
creatic NET-directed therapy [15].
To the best of our knowledge, as of June 2018, 
there are five ongoing studies, all recruiting pa-
tients, designed to explore the role of CAPTEM 
association in NENs (Tab. I), but none of these stud-
ies is specifically designed for unknown primary 
NET (NCT03387592, NCT03279601, NCT03079440, 
NCT02595424, NCT02358356).
This work presented two cases of atypical primary 
NET: the first was a primitive breast NET and the second 
was a primary NET of the retroperitoneum, both treated 
with CAPTEM. Primary neuroendocrine breast tumour 
was defined as a separate subtype of breast cancer in 
2003 by the World Health Organisation (WHO). This 
rare malignancy has an incidence of 0.3 to 1% of all 
breast cancers [16], occurring predominately in post-
menopausal women [17]. The histopathological assess-
ment of these tumours is difficult, and in most cases the 
correct diagnosis is made after proper examination of 
the postsurgical specimen [18]. 
In our experience CAPTEM determined a partial 
response in a heavily pre-treated neuroendocrine breast 
tumour. Also, the combination showed activity in reduc-
ing brain metastases. As is known, the TMZ significantly 
improves the survival of patients with newly diagnosed 
glioblastoma due to its relative penetration across the 
normal blood–brain barrier [19]. 
Primary NENs of the retroperitoneum are extremely 
rare, being more commonly the site of metastases 
from NETs with known primary. Only a few cases are 
reported in the literature [3]. 
As a consequence, the identification and treatment 
of these atypical NETs represent a clinical challenge 
and an essential need to identify the best treatment 
options. In clinical practice, therapeutic strategies for 
NENs of atypical primary are not well established, 
Table I. Ongoing studies exploring the efficacy and safety of the association of capecitabine and temozolomide in neuroendocrine 
tumours
Clinical trials 
gov identifier Title Conditions Interventions
NCT03387592 CAPTEM or FOLFIRI as second-line therapy 
in neuroendocrine carcinomas
Neuroendocrine carcinoma CPT-11/Calcio levofolinate/5-fluorouracil
Capecitabine/temozolomide 
NCT03279601 Study to compare capecitabine combined with 
dacarbazine (CAPDTIC) versus capecitabine 
combined temozolomide (CAPTEM) in advanced 
and metastatic gastrointestinal pancreatic and 
oesophageal neuroendocrine tumour
Gastrointestinal, 
pancreatic, or oesophageal 
neuroendocrine tumour
Capecitabine/dacarbazine
Capecitabine/temozolomide
NCT03079440 TEMCAP in grade 3 and low Ki-67 
gastroenteropancreatic neuroendocrine tumours
Gastrointestinal 
or pancreatic 
neuroendocrine carcinoma 
Capecitabine/temozolomide 
NCT02595424 Cisplatin, carboplatin, and etoposide 
or temozolomide and capecitabine in treating 
patients with Neuroendocrine carcinoma 
of the gastrointestinal tract or pancreas that 
is metastatic or cannot be removed by surgery
Gastrointestinal 
or pancreatic 
neuroendocrine carcinoma 
Capecitabine/temozolomide 
Carboplatin or cisplatin/etoposide
NCT02358356 Capecitabine ONTemozolomide radionuclide 
therapy octreotate lutetium-177 neuroendocrine 
tumours study (CONTROL NETS)
Intestinal or pancreatic 
neuroendocrine tumour
Lutetium-177 octreotate (177Lu-octreotate) 
peptide receptor radionuclide therapy 
(PRRT) plus capecitabine/temozolomide 
Capecitabine/temozolomide 
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so the CAPTEM regimen, which is active and well 
tolerated, can be considered for the treatment of 
these particular tumours after the failure of a first-line 
treatment.
Conclusions
Given the prior reports of the capecitabine and temo-
zolomide combination in G1/2 NETs, as well as our two 
cases, use of the CAPTEM regimen should be consid-
ered in patients with advanced, metastatic, well- or 
moderately-differentiated neuroendocrine tumours, 
including those of atypical primary, such as retroperito-
neal or breast origin that fail conventional medical and 
surgical therapies. Additional larger scale studies are 
needed to define the role of this chemotherapy regimen 
in the treatment of aggressive tumours.
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